期刊文献+

社区获得性肺炎合并与未合并全身炎症反应综合征患者N-末端脑钠肽前体水平变化及临床意义研究 被引量:13

The Level of N-Terminal Pro-Brain Natriuretic Peptide in Patients with Community-acquired Pneumonia Associated with or without Systemic Inflammatory Response Syndrome
下载PDF
导出
摘要 目的探讨社区获得性肺炎(CAP)合并与未合并全身炎症反应综合征(SIRS)患者N-末端脑钠肽前体(NT-proBNP)水平变化及临床意义。方法选择2012年1月—2013年3月我院住院的CAP患者148例,依据是否合并SIRS分为CAP非SIRS组78例和CAP合并SIRS组70例。采用酶联免疫吸附法测定两组患者的血清NT-proBNP水平,并行肺炎严重指数(PSI)评分。结果 CAP合并SIRS组NT-proBNP水平较CAP非SIRS组升高〔188.0(471.8)和62.5(135.3),P=0.009〕。CAP患者NT-proBNP水平与PSI评分呈正相关(r=0.292,P=0.001)。结论 CAP合并SIRS患者NT-proBNP水平升高,依据NT-proBNP水平可区分CAP是否合并SIRS,并可作为CAP患者病情严重程度及预后的判断指标。 Objective To explore the level of N -terminal pro -brain natriuretic peptide (NT -proBNP) in patients with community -acquired pneumonia (CAP) associated with our without systemic inflammatory response syndrome (SIRS) and its clinical significance. Methods One hundred and forty - eight CAP patients treated in our hospital between January 2012 and March 2013 were included in this study. Based on the presence of SIRS, the patients were divided into non - SIRS group ( n = 78 ) and SIRS group ( n = 70). The serum level of NT - proBNP was determined by ELISA test, and pneumonia severity index (PSI) score were determined. Results The serum level of NT - proBNP in SIRS group was significantly higher than that in non - SIRS group ( 188.0 (471.8) vs. 62. 5 ( 135.3 ), P = 0.009 3. The level of NT -proBNP was positively correlated with the PSI score (r = 0. 292, P = 0. 001 ). Conclusion The level of NT - proBNP was high in CAP patients with SIRS. The level of NT - proBNP may be the indicator of SIRS in CAP patients, which could be used to evaluate the severity or prognosis of CAP.
出处 《中国全科医学》 CAS CSCD 北大核心 2014年第2期144-147,共4页 Chinese General Practice
关键词 社区获得性感染 肺炎 全身炎症反应综合征 N-末端脑钠肽前体 Community - acquired infections Pneumonia System inflammatory response syndrome N - terminal pro - BNP
  • 相关文献

参考文献19

  • 1Lainscak M,Anker MS,Haehling S,et al.Biomarkers for chronic heart failure[J].Heart Fail Monit,2007,5(3):77-82.
  • 2Maisel AS,Krishnaswamy P,Nowak RM,et al.Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure[J].N Engl J Med,2002,347(3):161-167.
  • 3Nowak A,Breidthardt T,Christ-Crain M,et al.Direct comparison of three natriuretic peptides for prediction of short-and long-term mortality in patients with community-acquired pneumonia[J].Chest,2012,141(4):974-982.
  • 4社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量:3061
  • 5Bone RC,Balk RA,Cerra FB,et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[J].Chest,1992,101(6):1644-1655.
  • 6Yetkin O,Hacievliyagil SS,Gunen H.Assessment of B-type natriuretic peptide in patients with pneumonia[J].Int J Clin Pract,2008,62(3):488-491.
  • 7Leli C.Utility of brain natriuretic peptide as prognostic marker in community-acquired pneumonia and chronic obstructive pulmonary disease exacerbation patients presenting to the emergency department[J].Infez Med,2011,19(4):235-240.
  • 8Christ-Crain M,Breidthardt T,Stolz D,et al.Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia[J].J Intern Med,2008,264(2):166-176.
  • 9Hohenthal U,Hurme S,Helenius H,et al.Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumonia[J].Clin Microbiol Infect,2009,15(11):1026-1032.
  • 10Chen Y,Li C.Prognostic significance of brain natriuretic peptide obtained in the ED inpatients with SIRS or sepsis[J].Am J Emerg Med,2009,27(6):701-706.

二级参考文献24

  • 1沈定霞,罗燕萍,崔岩,赵莉萍,白立彦.分离产金属β-内酰胺酶的铜绿假单胞菌[J].中华医院感染学杂志,2004,14(1):86-88. 被引量:109
  • 2刘又宁,陈民钧,赵铁梅,王辉,王睿,刘庆锋,蔡柏蔷,曹彬,孙铁英,胡云建,修清玉,周新,丁星,杨岚,卓建生,唐英春,张扣兴,梁德荣,吕晓菊,李胜歧,刘勇,俞云松,魏泽庆,应可净,赵峰,陈萍,侯晓娜.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8. 被引量:789
  • 3Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
  • 4de Roux A,Marcos MA,Garcia E,et al.Viral community-acquired pneumonia in nonimmunocompromised adults.Chest,2004,125:1343-1351.
  • 5Ostrosky-Zeichner L,Alexander BD,Kett DH,et al.Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.Clin Infect Dis,2005,41:654-659.
  • 6Food and Drug Administration,HHS.Class Ⅱ Special Controls Guidance Document:serological assays for the detection of betaglucan.Fed Reqist,2004,69:56934-56936.
  • 7Mandell LA,Marrie TJ,Grossman RF,et al.Canadian guidelines for the initial management of community-acquired pneumonia:an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society.The Canadian CommunityAcquired Pneumonia Working Group.Clin Infect Dis,2000,31:383-421.
  • 8Woodhead M,Blasi F,Ewig S,et al.Guidelines for the management of adult lower respiratory tract infections.Eur Respir J,2005,26:1138-1180.
  • 9Mandell LA,Bartlett JG,Dowell SF,et al.Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.Clin Infect Dis,2003,37:1405-1433.
  • 10Fine MJ,Auble TE,Yealy DM,et al.A prediction rule to identify low risk patients with community-acquired pneumonia.N Engl J Med,1997,336:243-250.

共引文献3060

同被引文献135

引证文献13

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部